Recent news on Fulvestrant

Faslodex® Benefits Subset of Women Resistant to Aromatase Inhibitors  -  Feb 1, 2007
Cancer Consultants (press release),Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final

New Faslodex(TM) (fulvestrant) Data Fill 'treatment Gap' For Women ...  -  Jan 1, 2007
Medical News Today (press release),1) The data confirm that fulvestrant - an oestrogen receptor antagonist, and the first of a new type of endocrine therapy - is a valuable treatment option

Aromasin® and Faslodex® Similarly Effective and Safe As Second ...  -  Jan 2, 2007
Cancer Consultants (press release),According to results recently presented at the 2006 San Antonio Breast Cancer Symposium (SABCS), Aromasin (exemestane) and Faslodex (fulvestrant)

Analysis: Stopping breast-cancer return  -  Dec 19, 2006
Science Daily (press release)In these women, who had experienced disease progression after first-line treatment following cancer recurrence, the use of either fulvestrant or exemestane

Fulvestrant Equivalent to Exemestane in Second-Line Treatment ...  -  Dec 18, 2006
DG NewsOf these patients, 351 were randomly assigned to receive fulvestrant intramuscular injections at a 500 mg loading dose on day 1 and then at 250 mg on day 14

New Faslodex(TM) (Fulvestrant) Data Fill 'Treatment Gap' for Women ...  -  Dec 16, 2006
campus med,1) The data confirm that FASLODEX(TM) (fulvestrant) - an oestrogen receptor antagonist, and the first of a new type of endocrine therapy - is a valuable

Analysis: Stopping breast-cancer return  -  Dec 19, 2006
Science Daily (press release)In these women, who had experienced disease progression after first-line treatment following cancer recurrence, the use of either fulvestrant or exemestane

Aromasin® and Faslodex® Similarly Effective and Safe in Previously ...  -  Dec 18, 2006
Cancer Consultants (press release),According to results recently presented at the 2006 annual San Antonio Breast Cancer Symposium, Aromasin® (exemestane) and Faslodex® (fulvestrant)

SABCS: Aromasin and Faslodex Found Equivalent in Advanced Breast ...  -  Dec 16, 2006
MedPage Today,Advise patients who ask that this study suggests that Aromasin (exemestane) and Faslodex (fulvestrant) are equivalent when used to treat women with advanced

Women With Early Breast Cancer are More Likely to Remain Cancer ...  -  Nov 16, 2006
campus med,...development of its current anti-cancer therapies including 'ARIMIDEX' (anastrozole), 'CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant), 'NOLVADEX' (tamoxifen ...



Estrogen Can Kill Breast Cancer Cells Once Fueled by the Hormone  Apr 8, 2006
Women with these types of breast cancers are treated with drugs that that block estrogen, such as tamoxifen, fulvestrant, or aromatase inhibitors, causing the ... - eMaxHealth.com

A 62-Year-Old Woman With a New Diagnosis of Breast Cancer  Mar 21, 2006
Combinations of endocrine agents (eg, aromatase inhibitors plus the pure estrogen antagonist fulvestrant) are of interest, 53 as is the simultaneous use of ... - Journal of American Medical Association (subscription)

Optimising Herceptin-based Therapy in HER2-positive Metastatic ...  Feb 22, 2006
...will be looking at trastuzumab in combination with hormonal therapy, such as with tamoxifen, exemestane, anastrozole (TAnDEM trial), fulvestrant and letrozole ... - DG News

Mechanisms of estrogen in promoting cell death in breast cancer ...  Jan 15, 2006
...positive breast cancers ), and apoptosis of such cells can be induced with treatments that block estrogen, such as Tamoxifen, Fulvestrant, or aromatase ... - Xagena.it

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional